PT Siloam International Hospitals Tbk (SILO) Fair Value & Analysis
Healthcare · ID · Market cap 31.4T IDR
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 1,806 IDR to 1,885 IDR (+4.4%) since Jun 23, 2026. Share price −8.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,896 IDR – 2,960 IDR · fair‑value band 1,174 IDR – 2,356 IDR · the 2,220 IDR price screens above the 1,885 IDR fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PT Siloam International Hospitals Tbk (SILO) currently trades at 2,220 IDR, while our model-based Fair Value estimate is 1,885 IDR — implying the stock looks roughly 15.1% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Siloam International Hospitals Tbk generated revenue of 13.1T IDR at a net margin of 8.8%. Revenue grew 7.9% year over year. It earns a return on equity of 12.5%. Net debt stands at 477B IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardio…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Siloam International Hospitals Tbk reported revenue of 12.8T IDR in FY2025 versus 9.4T IDR in FY2021, a compound +8.2%/yr. Reported net income was 1.1T IDR in FY2025, compounding +13.3%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Siloam International Hospitals Tbk (SILO) undervalued?
What is the fair value of SILO?
What is the quality score of SILO?
What is the revenue of PT Siloam International Hospitals Tbk (SILO)?
What is the net profit margin of SILO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.